

# Affin Hwang **World Series -** **Global Healthscience** Fund

PRODUCED: AUGUST 2020


Out**think**. Out**perform**.



**AFFIN HWANG**  
**CAPITAL**  
Asset Management




# Key Drivers of the Global Healthcare Scene




### Aging demographics<sup>(1)</sup>

- 20% of the US population will be aged 65+ years by 2025, from just 8% in 1985.
- This segment of population spends 3x on healthcare as those under the age of 65.




### A battle against diseases<sup>(2)</sup>

- Rapid urbanisation, sedentary lifestyles, and rising obesity levels are fuelling an increase in chronic diseases.
- Global absolute spending on healthcare is expected to grow by 23% between 2015 and 2020 to reach US\$9 trillion.



### Innovation in new medicinal discovery<sup>(3)</sup>

- New drug discovery and development has not slowed.
- Rising therapy requests in areas including oncology, haematology and neurology among others.



### Advancement in medical procedures & robotics<sup>(4)</sup>


- Broad opportunities in the healthcare equipment industry. Projected market size for such devices is expected to reach US\$5 billion by 2021.
- Increasing application of robot-assisted surgery in the US market.

Source: (1) World Bank data and estimates, current as at 31 August 2019; Deloitte 2019 Outlook for Healthcare as at 31 January 2019. (2) Citi Private Bank: Safeguarding assets (2019), World Health Organization: Cancer – Key Facts, as at 12 September 2018; Deloitte, DBS CIO Insights 1Q19 as at January 2019. (3) Center for Drug Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services, “CDER New Drugs Program: 2018 Update”, as at 30 November 2018. (4) Source: Edwards Lifesciences, December 2019; Gartner Research, January 2017.

## Why Healthcare?

### Building greater portfolio resilience in a mature market cycle

Historically, the healthcare sector has shown low sensitivity to global growth, which makes it an appealing choice in a late cycle. In addition to relatively favourable valuations (in long-run average terms), the space is also supported by positive demographic and innovation trends, as well as a strong earnings outlook among defensive sectors.



Source: Lipper, as at 30 June 2020.  
Note: Past performance is not indication of future performance.

Source: BlackRock, using data from FactSet, BlackRock – Risk & Quantitative Analysis (RQA) as at 30 June 2020. Healthcare Sector refers to MSCI World Healthcare Index.  
Note: Past performance is not indication of future performance.

# OUR INVESTMENT STRATEGY

Affin Hwang World Series – Global Healthscience Fund invests

## Minimum 80% of the Fund's NAV

in the Target Fund, Blackrock Global Funds (BGF) World Healthscience Fund

Providing investors with ample diversification across the Healthcare Universe:



### Pharmaceuticals

- Companies engaged in the research, development or production of medicine.



### Healthcare Providers & Services

- Providers of health services such as hospitals, clinics and management companies.
- Also include names that provide I.T. services to healthcare providers.



### Biotechnology

- Products based on advanced genetic analysis and engineering.



### Medical Devices & Supplies

- Manufacturers of medical instruments and devices, including hospital supplies.
- Encompasses names enabling medicinal discovery by providing analytical tools and research services.

Scientific Experience of the Target Fund Manager, BlackRock, Inc.



20

average years of experience on average in scientific research, medicine and investing.

18

analysts across global platform dedicated to Healthcare and related themes.

1800+

quantitative analysts, risk management and trading professionals across the globe.

Source: BlackRock as of June 2020.

## Maximum 20% of the Fund's NAV

in money market instruments, deposits and / or cash

## Fund Facts

Fund Category / Type	Feeder (Wholesale) / Growth		
Investment Objective	The Fund seeks to achieve capital appreciation over the medium to long term period.		
Investor's Profile	<p>This Fund is suitable for investors who:</p> <ul style="list-style-type: none"> <li>▪ seek capital appreciation through investments in shares of companies whose predominant economic activity is in healthcare, pharmaceuticals, medical technology and supplies, and the development of biotechnology;</li> <li>▪ have a long-term investment horizon; and</li> <li>▪ have a high risk tolerance.</li> </ul>		
Investment Strategy	In line with its objective, the Fund will be investing a minimum of 80% of the Fund's NAV into the Target Fund and maximum of 20% of the Fund's NAV into money market instruments, deposits and / or liquid assets.		
Asset Allocation	<ul style="list-style-type: none"> <li>▪ A minimum of 80% of the Fund's NAV to be invested in the Target Fund; and</li> <li>▪ A maximum of 20% of the Fund's NAV to be invested in money market instruments, deposits and / or liquid assets.</li> </ul>		
Target Fund	Blackrock Global Funds (BGF) World Healthscience Fund		
Distribution Policy	The Fund is not expected to make distribution. However, incidental distribution may be declared whenever is appropriate.		
Minimum Investment	<b><u>USD Class</u></b>	<b><u>MYR Class</u></b>	<b><u>MYR Hedged-class</u></b>
	Initial: USD 5,000	Initial: MYR 5,000	Initial: MYR 5,000
	Additional: USD 1,000	Additional: MYR 1,000	Additional: MYR 1,000
	<b><u>SGD Hedged-class</u></b>	<b><u>AUD Hedged-class</u></b>	
	Initial: SGD 5,000	Initial: AUD 5,000	
	Additional: SGD 1,000	Additional: AUD 1,000	
Trustee	TMF Trustees Malaysia Berhad		

### WARNING STATEMENT

A copy of the Information Memorandum ("Info Memo") and Product Highlights Sheet ("PHS") can be obtained at Affin Hwang Asset Management's ("Affin Hwang AM") sales offices or at [www.affinhwangam.com](http://www.affinhwangam.com). Investors are advised to read and understand the contents of Affin Hwang World Series - Global Healthscience Fund's (or the "Fund") Info Memo dated 18 February 2019 and corresponding PHS before investing. There are fees and charges involved when investing in the Fund. Investors are advised to consider and compare the fees and charges as well of the risks carefully before investing. Investors should make their own assessment of the risks involved in investing and should seek professional advice, where necessary. The price of units and distribution payable, if any, may go down as well as up and past performance of the fund should not be taken as indicative of its future performance. The Securities Commission Malaysia has not reviewed this marketing/promotional material and takes no responsibilities for the contents of this marketing/promotional material and expressly disclaims all liability, however arising from this marketing/promotional material.

## #GrowWithUs

Follow us:



AffinHwangAM



affinhwangam

**Affin Hwang Asset Management Bhd 199701014290 (429786-T)**

Ground Floor, Menara Boustead, 69 Jalan Raja Chulan, 50200 Kuala Lumpur.

Toll Free Number: 1800 88 7080 T: +603 2116 6000 F: +603 2116 6100 W: [www.affinhwangam.com](http://www.affinhwangam.com)